EP0155189A2 - Expression of cell wall degrading proteins and host cells harboring dna encoding such protein - Google Patents
Expression of cell wall degrading proteins and host cells harboring dna encoding such protein Download PDFInfo
- Publication number
- EP0155189A2 EP0155189A2 EP85301827A EP85301827A EP0155189A2 EP 0155189 A2 EP0155189 A2 EP 0155189A2 EP 85301827 A EP85301827 A EP 85301827A EP 85301827 A EP85301827 A EP 85301827A EP 0155189 A2 EP0155189 A2 EP 0155189A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- host cell
- protein
- lysozyme
- cell wall
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
Definitions
- the present invention relates to the high level non-toxic expression of cell wall disrupting protein and means and methods for said expression.
- the invention further relates to the methods and means by which to lyse cell walls at will thereby providing a mechanism facilitating recovery of intracellular proteins.
- Lysozyme is one of several compounds responsible for disrupting or lysing cell walls.
- lysozyme is toxic in nature.
- bacterial viruses such as T4 phage kill bacteria using lysozyme to destroy the bacterial cell wall. Because of its toxic properities, it has heretofore been unknown to achieve high-level lysozyme expression in host cell culture, and further unknown to extract lysozyme in useful quantities from host cell cultures.
- the present invention provides a means for inducing a recombinant cell culture to produce lysozymes, which would ordinarily be expected to kill such host cells by means of destructing or lysing the cell wall structure.
- the production of lysozymes in accordance herewith is achieved with the unexpected result that the viability of the cells is not inhibited or destroyed so that useful quantities of the product, lysozyme, can be obtained.
- the present invention relates to the preparation of the polypeptide lysozyme in a recombinant host cell in which it would ordinarily function as a lyse/kill agent of the cells.
- the product lysozyme, as a product of recombinant DNA technology, as well as associated cloning vehicles and replicable expression vectors and the host cell harboring such vectors are covered by the present invention, in all of its aspects.
- One aspect of the invention that is especially useful is the high level non-toxic expression of products ordinarily toxic to the cell. Toxicity can be induced at any time during the non-toxic expression of such products by means of a freeze/thaw cycle.
- this invention provides a means by which to lyse cell walls at will thereby providing a mechanism facilitating recovery of intracellular products, including other recombinant products such as human growth hormone; various interferons, e.g., IFN-gamma, tissue plasminogen activator, hepatitis B surface antigen, and so on.
- interferons e.g., IFN-gamma, tissue plasminogen activator, hepatitis B surface antigen, and so on.
- Figure 1 illustrates the method for constructing the plasmid pT41ystacII.
- the accompanying drawing illustrates the construction of the plasmid pT41ystacII.
- a sample of cytosine containing T4 DNA (1, 2) was digested with the restriction endonuclease XhoI and a fragment of about 4,000 base pairs was isolated by agarose gel electrophoresis. The purified fragment was then cleaved with the restriction endonucleases RsaI and HindIII to yield a gel-purified fragment of about 700 base pairs which contained the T4 lysozyme gene.
- the plasmid pKCEAtetRXAP (3) was cleaved with the restriction endonuclease X baI, filled in with DNA polymerase I (Klenow fragment) and subsequently digested with the restriction endonuclease HindIII.
- the gel purified vector fragment was ligated with T4 DNA ligase to the 700 bp fragment to yield the plasmid pT4lysXHtrp.
- the plasmid phGH207-1 * (4) was cleaved with the restriction endonuclease EcoRI and elongated with DNA polymerase I (Klenow fragment), then cleaved with the restriction endonuclease BamHI, and the large vector fragment was purified by gel electrophoresis.
- the plasmid pT41ysXHtrp was cleaved with the restriction endonucleases XbaI and BamHI to yield a 1111 base pair fragment.
- a 14-base oligonucleotide primer was used in a primer repair reaction to delete the 97 bases of untranslated T4 DNA on the 5' end of the lysozyme gene (5).
- the primer was labeled using 32 P-ATP and polynucleotide kinase.
- the gel purified XbaI-BamHI fragment of pT4lysXHtrp was annealed to the labeled primer by heating to 95-100°C for 4 minutes followed by quick freezing. Nucleotide triphosphates were then added to the frozen mixture, which was then allowed to thaw. When the mix was partially thawed, DNA polymerase I (Klenow fragment) was added. The reaction was incubated at 37°C for 1.5 hours. EDTA was added to stop the reaction. The DNA was washed with phenol and chloroform, precipitated and washed with ethanol.
- the fragment was identified on an acrylamide gel by autoradiography. The identified fragment was eluted from the gel and quantified by scintillation counting. The resulting fragment was then digested with the restriction endonuclease EcoRI to yield a fragment of 230 base pairs which was isolated by gel electrophoresis.
- the plasmid pBR322 was digested with the restriction endonucleases EcoRI and BamHI and the 375 base pair fragment purified by gel electrophoresis. A three-way ligation reaction was performed with the three fragments to construct the pT4lysXRtrp ⁇ 5 ⁇ plasmid.
- This ligation mixture was used to transform E. coli K-12 294 (ATCC No. 31446). Plasmid DNA was isolated from the resulting transformants and applied to nitrocellulose paper. The paper was treated with 32 P labeled primer. When the nitrocellulose was gradually washed under conditions of increasing hybridization stringency, 37 positive sequences were seen. Six of the most strongly hybridizing positives were picked for M13 sequencing.
- the plasmid isolated from each of these strongly hybridizing clones was digested with the restriction endonucleases EcoRI and XbaI and the 230 base pair fragment was gel purified.
- the double stranded RF form of the Ml3rp10 DNA was also digested with EcoRI and X baI.
- the 230 base pair fragment was ligated into the digested M13 vector fragment overnight at room temperature.
- the ligation reaction mixtures . were used to transfect E. coli JHl01 (ATCC No. 33876), and plaques were picked and sequenced by standard methods. Only one of the positives analyzed by D NA sequencing had the correct sequence.
- the replicable expression vehicle which contains the EcoRI/XbaI fragment of the correct sequence was designated pT4lysXRtrpa ⁇ 5'.
- a 230 base pair fragment of the replicable cloning vehicle pT4lysXRtrp ⁇ 5' containing the 5' half of the lysozyme gene was isolated after treatment of the replicable cloning vehicle with the restriction with the restriction endonucleases XbaI/EcoRI and was cloned into the phage M13mp10.
- This fragment was ligated to the 1047 base pair fragment cleaved from the replicable cloning vehicle phGH907tacII with the restriction endonucleases XbaI and PstI, and to the large fragment of the replicable expression vector pT4LysXHtrp which had been cleaved with EcoRI and PstI, generating the replicable expression vector pT41ystacII.
- This replicable expression vector used to transform E. coli D1210 (ATCC No. 31449). The transformants were grown and selected on LB/ampicillin plates. Replicable expression vectors (REVs) were isolated from cells grown from the colonies and analyzed by restriction mapping.
- a colony of E. coli B1210/pT4lystacII was picked from a culture plate (LB broth/ampicillin) from a fresh transformation and grown overnight at 37° in five ml of LB (6) broth containing 20 micrograms/1 ampicillin. This culture was used to inoculate 1 liter of M9 medium (6) containing 20 micrograms/ml ampicillin in a 4 liter shake flask. When the culture reached an OD 550 of about 2, or late log phase growth, it was induced with the addition of 1mM isopropyl-beta-D-thiogalactoside (6). After one hour the cells were harvested by centrifugation and frozen.
- Frozen cells from 0.5 L of culture were lysed by addition to 20 ml 50 mM tris HC1, pH 7.5, 1 mM EDTA, 1 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride on ice.
- Two mls of five percent polyethylene imine hydrochloride (pH 7.5) was added with stirring and the suspension centrifuged at 10,000 rpm for 20 minutes in a Sorvall SS-34 rotor. The supernatant was passed over a DEAE-cellulose column and washed with 50 mM tris HCl, pH 7.5, 1 mM EDTA, 3 mM 2-mercaptoethanol.
- the flowthrough fractions containing 0.3 OD 280 or higher were pooled and adjusted to pH 5.2 with concentrated acetic acid. This was loaded onto a CM-cellulose column (10 ml bed volume in a 1 cm diameter column at 4°) equilibrated with 50 mM NaOAc, pH 5.5, 1 mM EDTA, 3 mM 2-mercaptoethanol. The column was washed with equilibration buffer, then eluted with a linear gradient of 0-0.5 M NaCl in equilibration buffer, total volume 100 ml, at a flow rate of 10 ml/hr. The fractions containing lysozyme activity (6) eluted at a NaCl concentration of about 0.25 M. These fractions contained as the major species a protein shown by SDS polyacrylamide gel electrophoresis to be of molecular weight about 19,000. The yield of protein was 4 milligrams.
- the molecular weight found for the recombinant T4 lysozyme was as expected based on the sequence of T4 lysozyme and its enzymatic activity as measured in the turbidity assay and compared to the activity of egg white lysozome. This was supported by amino acid compositional analysis.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
- The present invention relates to the high level non-toxic expression of cell wall disrupting protein and means and methods for said expression. The invention further relates to the methods and means by which to lyse cell walls at will thereby providing a mechanism facilitating recovery of intracellular proteins.
- Lysozyme is one of several compounds responsible for disrupting or lysing cell walls. Thus, lysozyme is toxic in nature. For example, it is known that bacterial viruses such as T4 phage kill bacteria using lysozyme to destroy the bacterial cell wall. Because of its toxic properities, it has heretofore been unknown to achieve high-level lysozyme expression in host cell culture, and further unknown to extract lysozyme in useful quantities from host cell cultures.
- The present invention provides a means for inducing a recombinant cell culture to produce lysozymes, which would ordinarily be expected to kill such host cells by means of destructing or lysing the cell wall structure. The production of lysozymes in accordance herewith is achieved with the unexpected result that the viability of the cells is not inhibited or destroyed so that useful quantities of the product, lysozyme, can be obtained.
- Thus, the present invention relates to the preparation of the polypeptide lysozyme in a recombinant host cell in which it would ordinarily function as a lyse/kill agent of the cells. The product lysozyme, as a product of recombinant DNA technology, as well as associated cloning vehicles and replicable expression vectors and the host cell harboring such vectors are covered by the present invention, in all of its aspects. One aspect of the invention that is especially useful is the high level non-toxic expression of products ordinarily toxic to the cell. Toxicity can be induced at any time during the non-toxic expression of such products by means of a freeze/thaw cycle. Thus, this invention provides a means by which to lyse cell walls at will thereby providing a mechanism facilitating recovery of intracellular products, including other recombinant products such as human growth hormone; various interferons, e.g., IFN-gamma, tissue plasminogen activator, hepatitis B surface antigen, and so on.
- Figure 1 illustrates the method for constructing the plasmid pT41ystacII.
- The accompanying drawing illustrates the construction of the plasmid pT41ystacII. A sample of cytosine containing T4 DNA (1, 2) was digested with the restriction endonuclease XhoI and a fragment of about 4,000 base pairs was isolated by agarose gel electrophoresis. The purified fragment was then cleaved with the restriction endonucleases RsaI and HindIII to yield a gel-purified fragment of about 700 base pairs which contained the T4 lysozyme gene. The plasmid pKCEAtetRXAP (3) was cleaved with the restriction endonuclease XbaI, filled in with DNA polymerase I (Klenow fragment) and subsequently digested with the restriction endonuclease HindIII. The gel purified vector fragment was ligated with T4 DNA ligase to the 700 bp fragment to yield the plasmid pT4lysXHtrp.
- The plasmid phGH207-1* (4) was cleaved with the restriction endonuclease EcoRI and elongated with DNA polymerase I (Klenow fragment), then cleaved with the restriction endonuclease BamHI, and the large vector fragment was purified by gel electrophoresis. The plasmid pT41ysXHtrp was cleaved with the restriction endonucleases XbaI and BamHI to yield a 1111 base pair fragment. A 14-base oligonucleotide primer was used in a primer repair reaction to delete the 97 bases of untranslated T4 DNA on the 5' end of the lysozyme gene (5). About 0.5 micrograms of the primer was labeled using 32P-ATP and polynucleotide kinase. The gel purified XbaI-BamHI fragment of pT4lysXHtrp was annealed to the labeled primer by heating to 95-100°C for 4 minutes followed by quick freezing. Nucleotide triphosphates were then added to the frozen mixture, which was then allowed to thaw. When the mix was partially thawed, DNA polymerase I (Klenow fragment) was added. The reaction was incubated at 37°C for 1.5 hours. EDTA was added to stop the reaction. The DNA was washed with phenol and chloroform, precipitated and washed with ethanol. The fragment was identified on an acrylamide gel by autoradiography. The identified fragment was eluted from the gel and quantified by scintillation counting. The resulting fragment was then digested with the restriction endonuclease EcoRI to yield a fragment of 230 base pairs which was isolated by gel electrophoresis. The plasmid pBR322 was digested with the restriction endonucleases EcoRI and BamHI and the 375 base pair fragment purified by gel electrophoresis. A three-way ligation reaction was performed with the three fragments to construct the pT4lysXRtrpΔ5` plasmid.
- This ligation mixture was used to transform E. coli K-12 294 (ATCC No. 31446). Plasmid DNA was isolated from the resulting transformants and applied to nitrocellulose paper. The paper was treated with 32P labeled primer. When the nitrocellulose was gradually washed under conditions of increasing hybridization stringency, 37 positive sequences were seen. Six of the most strongly hybridizing positives were picked for M13 sequencing.
- The plasmid isolated from each of these strongly hybridizing clones was digested with the restriction endonucleases EcoRI and XbaI and the 230 base pair fragment was gel purified. The double stranded RF form of the Ml3rp10 DNA was also digested with EcoRI and XbaI. The 230 base pair fragment was ligated into the digested M13 vector fragment overnight at room temperature. The ligation reaction mixtures . were used to transfect E. coli JHl01 (ATCC No. 33876), and plaques were picked and sequenced by standard methods. Only one of the positives analyzed by DNA sequencing had the correct sequence. The replicable expression vehicle which contains the EcoRI/XbaI fragment of the correct sequence was designated pT4lysXRtrpaΔ5'.
- A 230 base pair fragment of the replicable cloning vehicle pT4lysXRtrpΔ5' containing the 5' half of the lysozyme gene was isolated after treatment of the replicable cloning vehicle with the restriction with the restriction endonucleases XbaI/EcoRI and was cloned into the phage M13mp10. This fragment was ligated to the 1047 base pair fragment cleaved from the replicable cloning vehicle phGH907tacII with the restriction endonucleases XbaI and PstI, and to the large fragment of the replicable expression vector pT4LysXHtrp which had been cleaved with EcoRI and PstI, generating the replicable expression vector pT41ystacII. This replicable expression vector used to transform E. coli D1210 (ATCC No. 31449). The transformants were grown and selected on LB/ampicillin plates. Replicable expression vectors (REVs) were isolated from cells grown from the colonies and analyzed by restriction mapping. Colonies containing REVs with restriction fragments of the expected size, consistent with the desired final construction, were again grown. A SDS polyacrylamide gel with crude cellular protein from each IPTG.induced culture indicated the presence or absence of an induced protein of about 19,000 molecular weight. When it was later established that the T4 lysozyme isolated from a culture of these cells contained active lysozyme, the REV isolated from these cells was designated pT4lystacII.
- A colony of E. coli B1210/pT4lystacII was picked from a culture plate (LB broth/ampicillin) from a fresh transformation and grown overnight at 37° in five ml of LB (6) broth containing 20 micrograms/1 ampicillin. This culture was used to inoculate 1 liter of M9 medium (6) containing 20 micrograms/ml ampicillin in a 4 liter shake flask. When the culture reached an OD550 of about 2, or late log phase growth, it was induced with the addition of 1mM isopropyl-beta-D-thiogalactoside (6). After one hour the cells were harvested by centrifugation and frozen.
- Frozen cells from 0.5 L of culture were lysed by addition to 20 ml 50 mM tris HC1, pH 7.5, 1 mM EDTA, 1 mM 2-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride on ice. Two mls of five percent polyethylene imine hydrochloride (pH 7.5) was added with stirring and the suspension centrifuged at 10,000 rpm for 20 minutes in a Sorvall SS-34 rotor. The supernatant was passed over a DEAE-cellulose column and washed with 50 mM tris HCl, pH 7.5, 1 mM EDTA, 3 mM 2-mercaptoethanol.
- The flowthrough fractions containing 0.3 OD280 or higher were pooled and adjusted to pH 5.2 with concentrated acetic acid. This was loaded onto a CM-cellulose column (10 ml bed volume in a 1 cm diameter column at 4°) equilibrated with 50 mM NaOAc, pH 5.5, 1 mM EDTA, 3 mM 2-mercaptoethanol. The column was washed with equilibration buffer, then eluted with a linear gradient of 0-0.5 M NaCl in equilibration buffer, total volume 100 ml, at a flow rate of 10 ml/hr. The fractions containing lysozyme activity (6) eluted at a NaCl concentration of about 0.25 M. These fractions contained as the major species a protein shown by SDS polyacrylamide gel electrophoresis to be of molecular weight about 19,000. The yield of protein was 4 milligrams.
- The molecular weight found for the recombinant T4 lysozyme was as expected based on the sequence of T4 lysozyme and its enzymatic activity as measured in the turbidity assay and compared to the activity of egg white lysozome. This was supported by amino acid compositional analysis.
- The following references are cited in the foregoing specification by parenthetical numerals corresponding to those listed below. All of these references are hereby incorporated by reference.
-
- 1. 0' Farrell, et al., Molec. Gen. Genet. 179, 421-435.
- 2. Owen, et al., J. Mol. Biol. 165, 229-248.
- 3. Cabilly, Shmuel, et al., Generation of Antibody Activity from Immunoclobulin Polypeptide Chains Produced in Escherichia coli Proc. Natl. Acad. Sci. (USA), 81, 3273.
- 4. Gray, et al., Bio/Technology, 2, 161- 165.
- 5. Goeddel, et al., Nucleic Acids Res., 8 4057-4074.
- 6. Miller, J. H., Experiments in Molecular Genetics, (1972), Cold Spring Harbor Laboratory.
Claims (10)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59013884A | 1984-03-16 | 1984-03-16 | |
US590138 | 1984-03-16 | ||
US64978684A | 1984-09-11 | 1984-09-11 | |
US649786 | 1984-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0155189A2 true EP0155189A2 (en) | 1985-09-18 |
EP0155189A3 EP0155189A3 (en) | 1987-09-16 |
Family
ID=27080766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85301827A Withdrawn EP0155189A3 (en) | 1984-03-16 | 1985-03-15 | Expression of cell wall degrading proteins and host cells harboring dna encoding such protein |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP0155189A3 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0181634A2 (en) * | 1984-11-14 | 1986-05-21 | Takeda Chemical Industries, Ltd. | Synthetic gene for human lysozyme |
EP0208472A1 (en) * | 1985-06-26 | 1987-01-14 | Sumitomo Chemical Company, Limited | Microbiological process for production of human lysozyme |
EP0222366A2 (en) * | 1985-11-12 | 1987-05-20 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for the preparation of human lysozyme |
EP0368224A2 (en) * | 1988-11-10 | 1990-05-16 | Hoechst Aktiengesellschaft | Streptomycete lysozyme gene, method for its isolation and its use |
US4945051A (en) * | 1986-06-30 | 1990-07-31 | Takeda Chemical Industries, Ltd. | Production of human lysozyme |
EP0389377A1 (en) * | 1989-03-22 | 1990-09-26 | Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada | Excretion of proteins from yeast cells |
WO1993024633A2 (en) * | 1992-05-29 | 1993-12-09 | Center For Innovative Technology | METHOD FOR PRODUCTION AND RECOVERY OF POLY-β-HYDROXYBUTYRATE FROM TRANSFORMED $i(ESCHERICHIA COLI) |
US5891686A (en) * | 1993-03-24 | 1999-04-06 | Center For Innovative Technology | Method of production of poly-β-hydroxyalkanoate copolymers |
WO2000024769A2 (en) * | 1998-10-28 | 2000-05-04 | Genentech, Inc. | Process for recovering heterologous polypeptide from bacterial refractile particles |
WO2000024873A1 (en) * | 1998-10-28 | 2000-05-04 | Genentech, Inc. | Process for recovering heterologous polypeptides from bacterial cells |
EP2314602A1 (en) | 2003-11-21 | 2011-04-27 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
EP2468869A1 (en) | 2007-01-31 | 2012-06-27 | Pfenex, Inc. | Bacterial leader sequences for increased expression |
US8318481B2 (en) | 2007-12-07 | 2012-11-27 | Pfenex Inc. | High copy number self-replicating plasmids in pseudomonas |
EP2615172A1 (en) | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US10041102B2 (en) | 2002-10-08 | 2018-08-07 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0043075A2 (en) * | 1980-06-25 | 1982-01-06 | Studiengesellschaft Kohle mbH | Process for increasing the incorporation and expression of genetic material in nuclei of intact cells with the aid of liposomes |
EP0049619A2 (en) * | 1980-10-03 | 1982-04-14 | Eli Lilly And Company | Method for stabilizing and selecting host cells containing recombinant DNA |
DE3309501A1 (en) * | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | Plasmid vectors for the cloning, identification and expression of genes |
EP0181634A2 (en) * | 1984-11-14 | 1986-05-21 | Takeda Chemical Industries, Ltd. | Synthetic gene for human lysozyme |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE901223A (en) * | 1984-12-06 | 1985-03-29 | Labofina Sa | Transformed yeast able to produce lysozyme - contg. plasmid which includes N-acetyl-muramidase gene |
-
1985
- 1985-03-15 EP EP85301827A patent/EP0155189A3/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0043075A2 (en) * | 1980-06-25 | 1982-01-06 | Studiengesellschaft Kohle mbH | Process for increasing the incorporation and expression of genetic material in nuclei of intact cells with the aid of liposomes |
EP0049619A2 (en) * | 1980-10-03 | 1982-04-14 | Eli Lilly And Company | Method for stabilizing and selecting host cells containing recombinant DNA |
DE3309501A1 (en) * | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | Plasmid vectors for the cloning, identification and expression of genes |
EP0181634A2 (en) * | 1984-11-14 | 1986-05-21 | Takeda Chemical Industries, Ltd. | Synthetic gene for human lysozyme |
Non-Patent Citations (6)
Title |
---|
CHEMICAL ABSTRACTS, vol. 96, no. 19, 10th May 1982, page 191, abstract no. 156516r, Columbus, Ohio, US; C.H. CLARKE: "Preferred sites of frameshift mutagenesis in AT- and GC-rich microbial DNA", & J. THEOR. BIOL. 1982, 94(3), 519-34 * |
CHEMICAL ABSTRACTS, vol. 98, no. 3, 17th January 1983, page 147, abstract no. 12350a, Columbus, Ohio, US; P.D. MATTHIAS et al.: "Transient expression of the chicken lysozyme gene after transfer into human cells", & EMBO J. 1982, 1(10), 1207-12 * |
CHEMICAL ABSTRACTS, vol. 99, no. 1, 4th July 1983, page 126, abstract no. 1133b, Columbus, Ohio, US; J.E. OWEN et al.: "Nucleotide sequence of the lysozyme gene of bacteriophage T4. Analysis of mutations involving repeated sequences", & J. MOL. BIOL. 1983, 165(2), 229-48 * |
CHEMICAL ABSTRACTS, vol. 99, no. 9, 29th August 1983, page 271, abstract no. 66438z, Columbus, Ohio, US; B. SZEWCZYK et al.: "Purification and some properties of bacteriophage T4 particle-associated lysozyme", & EUR. J. BIOCHEM. 1983, 133(3), 717-22 * |
MIAMI WINTER SYMPOSIA, FROM GENE TO PROTEIN: TRANSLATION INTO BIOTECHNOLOGY, vol. 19, pages 309-327, edited by F. Ahmad et al., Academic Press, New York, US; H. DE BOER et al.: "Construction of three hybrid promoters and their properties in Escherichia coli" * |
SCIENCE, vol. 226, 2nd November 1984, pages 555-557; L.J. PERRY et al.: "Disulfide bond engineered into T4 lysozyme: Stabilization of the protein toward thermal inactivation" * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0181634A2 (en) * | 1984-11-14 | 1986-05-21 | Takeda Chemical Industries, Ltd. | Synthetic gene for human lysozyme |
EP0181634A3 (en) * | 1984-11-14 | 1987-09-09 | Takeda Chemical Industries, Ltd. | Synthetic gene for human lysozyme |
EP0208472A1 (en) * | 1985-06-26 | 1987-01-14 | Sumitomo Chemical Company, Limited | Microbiological process for production of human lysozyme |
EP0222366A2 (en) * | 1985-11-12 | 1987-05-20 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Process for the preparation of human lysozyme |
EP0222366A3 (en) * | 1985-11-12 | 1987-09-30 | Boehringer Ingelheim International G.M.B.H | Human lysozyme |
US5618712A (en) * | 1985-11-12 | 1997-04-08 | Boehringer Ingelheim Zentrale Gmbh | Human lysozyme |
US4945051A (en) * | 1986-06-30 | 1990-07-31 | Takeda Chemical Industries, Ltd. | Production of human lysozyme |
EP0368224A3 (en) * | 1988-11-10 | 1991-12-27 | Hoechst Aktiengesellschaft | Streptomycete lysozyme gene, method for its isolation and its use |
EP0368224A2 (en) * | 1988-11-10 | 1990-05-16 | Hoechst Aktiengesellschaft | Streptomycete lysozyme gene, method for its isolation and its use |
EP0389377A1 (en) * | 1989-03-22 | 1990-09-26 | Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada | Excretion of proteins from yeast cells |
WO1993024633A2 (en) * | 1992-05-29 | 1993-12-09 | Center For Innovative Technology | METHOD FOR PRODUCTION AND RECOVERY OF POLY-β-HYDROXYBUTYRATE FROM TRANSFORMED $i(ESCHERICHIA COLI) |
WO1993024633A3 (en) * | 1992-05-29 | 1994-03-17 | Innovative Tech Center | METHOD FOR PRODUCTION AND RECOVERY OF POLY-β-HYDROXYBUTYRATE FROM TRANSFORMED $i(ESCHERICHIA COLI) |
US5891686A (en) * | 1993-03-24 | 1999-04-06 | Center For Innovative Technology | Method of production of poly-β-hydroxyalkanoate copolymers |
US6180367B1 (en) | 1998-10-28 | 2001-01-30 | Genentech, Inc. | Process for bacterial production of polypeptides |
US8183029B2 (en) | 1998-10-28 | 2012-05-22 | Genentech, Inc. | Replicable expression vector for bacterial expression of a mammalian polypeptide |
WO2000024769A3 (en) * | 1998-10-28 | 2000-08-17 | Genentech Inc | Process for recovering heterologous polypeptide from bacterial refractile particles |
WO2000024769A2 (en) * | 1998-10-28 | 2000-05-04 | Genentech, Inc. | Process for recovering heterologous polypeptide from bacterial refractile particles |
US6258560B1 (en) | 1998-10-28 | 2001-07-10 | Genentech, Inc. | Process for bacterial production of polypeptides |
EP1323820A2 (en) * | 1998-10-28 | 2003-07-02 | Genentech Inc. | Process for facillitated recovery of heterologous proteins from bacterial cells |
EP1323820A3 (en) * | 1998-10-28 | 2003-07-09 | Genentech Inc. | Process for facillitated recovery of heterologous proteins from bacterial cells |
US7858339B1 (en) | 1998-10-28 | 2010-12-28 | Genentech, Inc. | Process for bacterial production of polypeptides |
WO2000024873A1 (en) * | 1998-10-28 | 2000-05-04 | Genentech, Inc. | Process for recovering heterologous polypeptides from bacterial cells |
US10041102B2 (en) | 2002-10-08 | 2018-08-07 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
EP2327718A1 (en) | 2003-11-21 | 2011-06-01 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
EP2336153A1 (en) | 2003-11-21 | 2011-06-22 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
EP2314602A1 (en) | 2003-11-21 | 2011-04-27 | Pfenex, Inc. | Improved expression systems with SEC-system secretion |
US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
US9109229B2 (en) | 2004-07-26 | 2015-08-18 | Pfenex Inc. | Process for improved protein expression by strain engineering |
EP2468869A1 (en) | 2007-01-31 | 2012-06-27 | Pfenex, Inc. | Bacterial leader sequences for increased expression |
EP2615172A1 (en) | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US10689640B2 (en) | 2007-04-27 | 2020-06-23 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US8318481B2 (en) | 2007-12-07 | 2012-11-27 | Pfenex Inc. | High copy number self-replicating plasmids in pseudomonas |
Also Published As
Publication number | Publication date |
---|---|
EP0155189A3 (en) | 1987-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0155189A2 (en) | Expression of cell wall degrading proteins and host cells harboring dna encoding such protein | |
Morinaga et al. | Improvement of oligonucleotide-directed site-specific mutagenesis using double-stranded plasmid DNA | |
JP3500148B2 (en) | Improved enzyme for 2-keto-L-gulonic acid production | |
Yeung et al. | The purification of the Escherichia coli UvrABC incision system | |
Salas | A new mechanism for the initiation of replication of Φ 29 and adenovirus DNA: priming by the terminal protein | |
Cheng et al. | Positive-selection cloning vehicle useful for overproduction of hybrid proteins | |
Rogers et al. | Cloning of the exonuclease III gene of Escherichia coli | |
Aisaka et al. | Cloning and constitutive expression of the N-acetylneuraminate lyase gene of Escherichia coli | |
Jagusztyn-Krynicka et al. | Streptococcus mutans serotype c tagatose 6-phosphate pathway gene cluster | |
Hesman et al. | Cloning, characterization, and nucleotide sequence analysis of a Zymomonas mobilis phosphoglucose isomerase gene that is subject to carbon source-dependent regulation | |
Jack et al. | Overexpression, purification and crystallization of Bam HI endonuclease | |
Wang et al. | Cloning and expression of L-asparaginase gene in Escherichia coli | |
JP3822006B2 (en) | Method for producing cytidine 5'-choline diphosphate | |
JP2551746B2 (en) | Improved plasmid vector and its use | |
Haggård-Ljungquist et al. | The P2 phage old gene: sequence, transcription and translational control | |
US5508176A (en) | Recombinant DNA, transformed host microorganism and method for producing a polypeptide having mutarotase activity | |
JP2591713B2 (en) | DNA sequences, recombinant DNA molecules and methods for the production of the enzyme mutarotase from Acinetobacter calcoaceticus | |
Ishii et al. | Purification and characterization of the N gene product of bacteriophage lambda | |
Brush et al. | Bacteriophage T4 deoxynucleotide kinase: gene cloning and enzyme purification | |
EP0155190A2 (en) | Non-naturally occurring zymogens and methods and materials for their construction | |
JP3910248B2 (en) | Method for producing DNA nested deletion by in vitro reaction using transposase | |
JP2988951B2 (en) | Production of heterologous proteins in Escherichia coli | |
WO1988008881A1 (en) | Extraction of granulocyte macrophage colony stimulating factor from bacteria | |
JP2904437B2 (en) | DNA fragment containing sucrose phosphorylase gene | |
JPH0679556B2 (en) | Plasmid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19860818 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19890421 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19890902 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WETZEL, RONALD BURNELL |